Biosimilars in the pharmacy benefit employers driving appropriate use and transparency.
Despite the fact that less than 2 percent of the U.S. population uses biologic drugs, they account for 26 percent of national prescription drug spending. Biosimilars can expand options, enhance affordability, and increase access to therapy. It’s been estimated that biosimilars could save patients and the healthcare system from $54 to $250 billion over their first 10 years on the market without compromising outcomes.
The National Alliance of Healthcare Purchaser Coalitions outlines steps employers can take to benefit from the savings biosimilars offer.